Progyny, Inc. - PGNY STOCK NEWS

Progyny reported Q3 2024 revenue of $286.6 million, up 2.0% year-over-year, with net income of $10.4 million. The company secured over 80 new clients and 1.1 million new covered lives during the sales season. However, lower-than-expected revenue and profitability occurred as members took longer to progress through treatments. Gross margin decreased to 20.7% from 22.3% in Q3 2023. The company was selected by two health plans as their preferred partner and saw 1.5 million lives adopt their newest maternity and menopause programs for 2025. For full-year 2024, revenue guidance was revised to $1.135-1.150 billion.

Progyny (Nasdaq: PGNY) has scheduled its Q3 2024 financial results announcement for Tuesday, November 12, 2024, after market close. The company will host a conference call at 4:45 P.M. ET, accessible to U.S. participants at 1.866.825.7331 and international participants at 1.973.413.6106 (passcode: 265484). An audio replay will be available through November 19, 2024. Progyny is a fertility, family building, and women's health benefits provider that offers comprehensive solutions including concierge support, coaching, and access to premier healthcare specialists.

Progyny announced its Q2 2024 financial results, showing an 8.8% increase in revenue to $304.1 million and a 13% rise in gross profit to $68.3 million. Net income increased to $16.5 million, or $0.17 per diluted share, while Adjusted EBITDA rose 15% to $54.5 million. The company noted strong demand for fertility treatments and women's health solutions. However, it observed a lower revenue per utilizing member, affecting expectations for the second half of the year.

Progyny's board authorized a $100 million stock repurchase, adding to the 6.8 million shares already repurchased. The company also provided guidance for the full year 2024, projecting revenue of $1.165-$1.20 billion, net income of $55.4-$62.4 million, and Adjusted EBITDA of $199-$209 million.

Progyny (Nasdaq: PGNY) and The Broken Brown Egg have launched the 2024 Awareness, Hope, and Activism (AHA) Grant™ to support BIPOC individuals and couples in family building. Now in its third year, the grant aims to address barriers faced by Black individuals in accessing fertility care, including financial constraints, healthcare disparities, and social stigmas.

The grant provides education, specialized treatment, financial assistance, and emotional support. Recipients will receive medication support through Alto Pharmacy and unlimited access to a dedicated Progyny Patient Care Advocate. The application is open from July 24 to August 10, 2024, for U.S. citizens and legal residents aged 45 or younger. Winners will be announced in September, chosen by a panel of BIPOC infertility advocates and physicians.

Progyny, Inc. (Nasdaq: PGNY), a leading fertility, family building, and women's health benefits solution provider, has announced its plans to report Q2 2024 financial results on August 6, 2024, after market close. The company will host a conference call at 4:45 P.M. ET (1:45 P.M. PT) to discuss the results.

Interested participants can join the call using specific dial-in numbers and passcode. A live webcast and archive of the call will be available on the company's investor relations website. Progyny is recognized for its innovative approach to fertility and women's health benefits, focusing on comprehensive solutions that benefit employers, patients, and physicians while optimizing clinical outcomes and reducing healthcare costs.

Progyny, Inc. (Nasdaq: PGNY) has announced its inaugural Investor Day to be held on August 12, 2024, in New York City. The event will run from 9:00 A.M. to 1:00 P.M. Eastern Time. During the Investor Day, Progyny's executives and senior leadership team will provide an overview of the company's business and growth opportunities. A live Q&A session will follow the presentations. Due to space restrictions, in-person attendance is to two representatives per firm, and prior registration is required. Interested parties should email their request to InvestorDay@progyny.com. A live audiocast and replay of the event will be accessible via Progyny's investor relations website.

Progyny (Nasdaq: PGNY) has expanded its global reach by acquiring Apryl, a Berlin-based fertility benefits platform. This acquisition bolsters Progyny's ability to provide comprehensive, concierge-level fertility and family-building support to multinational employers and employees in over 100 countries. The enhanced services include holistic support across various fertility-related needs, seamless integration with local laws, and secure financial processing. The move aims to ensure equitable and consistently high-quality benefits for employees worldwide.

Progyny (NASDAQ: PGNY) published findings from its 2024 LGBTQ+ family building survey, which included responses from over 1,100 LGBTQ+ individuals in the U.S. The survey revealed that most respondents face significant challenges such as high costs, inadequate access to care, and lack of mental health support. Key data points include 76% being concerned about family building costs, 54% hindered by these costs, 83% willing to change employers for better benefits, and 85% considering a second job for employer-sponsored care. Many are also exploring adoption (48%) and surrogacy (29%). Progyny emphasizes the importance of inclusive and comprehensive family building benefits offered by employers to support LGBTQ+ employees, promoting workplace inclusion and loyalty.

Kindbody, a leading fertility clinic network, announces Founder Gina Bartasi's return as CEO amidst significant company growth. Expected 2024 revenue is projected between $225-250 million, achieving profitability after years of investment. Key promotions include Gina Bruzzichesi to President and Haleigh Tebben to Chief Commercial Officer. Kindbody, serving 121 employers and over 3.1 million lives, operates 35 clinics globally. The company's proprietary tech platform, KindEMR, enhances care standardization and patient experience. Their AI initiatives aim to optimize fertility treatment outcomes.